Amphivena Therapeutics

Amphivena Therapeutics, a subsidiary of Affimed Therapeutics, develops treatments to address hematologic malignancies.

Amphivena Therapeutics Inc., a newly created subsidiary of venture-backed Affimed Therapeutics AG , has raised $14 million in Series A financing and has granted Janssen Biotech an exclusive option to acquire the company. Affimed has used its TandAb technology to develop a pipeline of treatments for diseases such as Hodgkin lymphoma and non-Hodgkin lymphoma. Its new subsidiary, Amphivena, will use this technology to address hematologic malignancies, but specifics about its drug program and the indications it will pursue haven't been disclosed....